Skip to content

Study · Not a test of the peptide alone · 1979

2 results

Adrenocortical function tests in dogs with hyperfunctioning adrenocortical tumours.

Meijer JC, Lubberink AA, Rijnberk A, Croughs RJ

The Journal of endocrinology1 Mar 1979Cited by 21 (Europe PMC)

PMID438707 (opens in a new tab)DOI10.1677/joe.0.0800315 (opens in a new tab)PepBankPUB-00438707
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

  1. 01AnimalNot a test of Cosyntropin aloneAnimal study (in vivo)Activity measurement

    In dogs with adrenocortical tumours, eight of nine responded to tetracosactide administration.

    In plain wordsIn dogs with adrenal tumours, eight of nine showed a cortisol response to tetracosactide.

    Peptide
    Cosyntropin
    Outcome
    IncreaseCortisol response to tetracosactide
    Study

    dogn = 9

    Hyperadrenocorticism due to adrenocortical tumours
    Outcome group
    Adrenal Function · Endocrine and hormones

    Measurements

    Responders
    8 dogs
    nine tested

    Source sentences

    Summary
    Eight out of the nine dogs responded to tetracosactide administration, three responded supranormally
    1 context sentence
    Summary · context
    The response has been studied in nine dogs with hyperadrenocorticism due to adrenocortical tumours to the administration of dexamethasone, insulin, lysine-vasopressin and tetracosactide by measuring the changes in plasma cortisol concentration.

    In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.

  2. 02AnimalNot a test of Cosyntropin aloneAnimal study (in vivo)Activity measurement

    In dogs with adrenocortical tumours, three of nine showed supranormal responses to tetracosactide.

    In plain wordsIn dogs with adrenal tumours, three of nine had unusually high cortisol responses to tetracosactide.

    Peptide
    Cosyntropin
    Outcome
    IncreaseSupranormal cortisol response
    Study

    dogn = 9

    Hyperadrenocorticism due to adrenocortical tumours
    Outcome group
    Adrenal Function · Endocrine and hormones

    Measurements

    Supranormal responders
    3 dogs
    nine tested

    Source sentences

    Summary
    Eight out of the nine dogs responded to tetracosactide administration, three responded supranormally
    1 context sentence
    Summary · context
    The response has been studied in nine dogs with hyperadrenocorticism due to adrenocortical tumours to the administration of dexamethasone, insulin, lysine-vasopressin and tetracosactide by measuring the changes in plasma cortisol concentration.

    In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.